Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

Dec 01 2020

• By Michael McCaughan

a long time ago on vintage typewriter (shutterstock) — • Source: Shutterstock

Related Content

Aducanumab Fall-Out: An Inexpedient Use Of ‘Expedited’ Review

Nov 12 2020

Two Steps Forward, One Step Back: FDA, Actavis Antibiotic Plan Goes A Bit Too Far For Committee

Jan 06 2015

Actavis’ <em>Avycaz</em> Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic

Mar 02 2015

WARNER LAMBERT's COGNEX: FDA ADVISORY COMMITTEE UNABLE TO RECOMMEND APPROVAL

Mar 18 1991

WARNER-LAMBERT’s COGNEX WILL REQUIRE WEEKLY BLOOD MONITORING AT OUTSET OF TREATMENT; ALZHEIMER THERAPY APPROVED SEPT. 9 WILL COST $3.05/DAY DIRECT PRICE

Sep 13 1993

Related Companies

Biogen, Inc.

Pfizer Inc.

Actavis Group

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Advisory Committees Drug Approval Standards Drug Review FDA Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window